Incidence and outcomes of sars-cov-2 infection in patients with metastatic castration-resistant prostate cancer
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Background : Cancer patients are at increased risk of complicated SARS-CoV-2 infection but it is still unclear if the risk of mortality is influenced by cancer type or ongoing anti-cancer treatments. An interesting debate concerning the potential relationship between androgen deprivation therapy (ADT) and SARS-CoV-2 infection has recently been opened in the case of prostate cancer (PC), and the aim of this multi-centre cohort study was to investigate the incidence and outcomes of SARS-CoV-2 infection in patients with metastatic castration-resistant PC (mCRPC). Patients and methods : We retrospectively reviewed the clinical records of mCRPC patients who developed SARS-CoV-2 infection, and recorded their baseline clinical characteristics, their history of PC and SARS-CoV-2 infection, and their oncological status and treatment at the time of infection. The primary study endpoint was the death rate and the possible impact of the patients’ PC-related history and treatments on mortality. Results : Thirty-four of the 1,433 mCRPC patients attending the participating centres (2.3%) developed SARSCoV-2 infection, 22 (64.7%) of whom were hospitalised. Most of the patients were symptomatic, the most frequent symptoms being fever (70.6%), dyspnea (61.8%), cough (52.9%), and fatigue (38.2%). After a median follow-up of 21 days (IQR 13-41), 13 patients had died (38.2%), 17 recovered (50.0%), and four (11.7%) were still infected. The number of treatments previously administered for mCRPC had a significant impact on mortality (p = 0.004). Conclusions : Our findings contribute additional data to the current debate concerning the postulated protective role of ADT, which seems to be less in patients with metastatic PC.
European Journal of Cancer , article en libre accès, 2019